Supplementary Table 1. Baseline demographic and clinical characteristics of subpopulation (samples available) compared to all patients of CAMERA study.

	Subgroup	All patients
Characteristic	n = 74	n = 299
Intensive strategy (% (n))	53% (39)	51% (151)
Female gender (% (n))	70% (52)	67% (201)
Age (years)	53 (15)	53 (15)
RF positive (% (n))	68% (50)	62% (185)
Morning stiffness (min)	97 (61)	92 (61)
VAS general (mm)	58 (23)	54 (24)
VAS pain (mm)	54 (27)	51 (27)
TJC28	9 (6)	13 (7)
SJC28	10 (5)	13 (7)
ESR (mm/h)	39 (29)	37 (26)
DAS28	5.6 (1.0)	5.6 (1.1)
Median radiographic score (IQR)	0 (0-0)	0 (0-0)
EULAR response (at 6 months)		
Good response (% (n))	39% (29)	37% (101)
Moderate response (% (n))	32% (24)	41% (113)
No response (% (n))	28% (21)	22% (59)

Mean (standard deviation, SD) is shown for all continuous variables, except for radiographic score where median (interquartile range, IQR) is shown. For all categorical variables % (number) of patients is shown.

Subgroup= patients who had available serum samples for this analysis at either baseline, 6 months or both; All patients= all patients officially participating the CAMERA study; RF= rheumatoid factor; VAS= visual analogue scale (0-100, latter is worst score); TJC= tender joint count, based on 28 joints; SJC= swollen joint count, based on 28 joints; DAS28= disease activity score based on 28 joint count; ESR= erythrocyte sedimentation rate; Radiographic score= Sharp/van der Heijde score; EULAR response= based on the EULAR definition, calculated at 6 months of treatment.

	Assay	Median	Units	
Analyte	Concentration			
Calprotectin	MSD Panel E	1.234E+07	pg/mL	
CCL22	MSD Panel C	1246	pg/mL	
CRP	MSD Panel B	1.163E+07	pg/mL	
EGF	MSD Panel A	229.7	pg/mL	
ICAM-1	MSD Panel B	3.543E+05	pg/mL	
IL-1B	MSD Panel A	0.3632	pg/mL	
IL-1RA	ELISA (R&D Systems)	287.2	pg/mL	
IL-6	MSD Panel A	38.25	pg/mL	
IL-6R	MSD Panel C	3.901E+04	pg/mL	
IL-8	MSD Panel A	10.65	pg/mL	
Leptin	MSD Panel A	1.259E+04	pg/mL	
MMP1	MSD Panel C	7895	pg/mL	
MMP3	MSD Panel C	4.151E+04	pg/mL	
PYD	ELISA (Quidel)	3.239E+00	nmol/L	
Resistin	MSD Panel C	6502	pg/mL	
SAA	MSD Panel B	6.259E+06	pg/mL	
TNF-R1	MSD Panel C	1931	pg/mL	
VCAM-1	MSD Panel B	5.426E+05	pg/mL	
VEGF-A	MSD Panel A	354.4	pg/mL	
YKL-40	MSD Panel C	6.243E+04	pg/mL	

Supplementary Table 2. Biomarker assay sources and median concentrations.

Median concentration (pg/mL) is shown for all analytes. MSD = Meso Scale Discovery.